Triple Action in Type 2 Diabetes Management: Canagliflozin in Focus

Menarini Group |
Tuesday

Chair: Stefano Del Prato (ITA) 18:30 – 18:32 General introduction: from active to proactive diabetes management Stefano Del Prato (ITA) 18:32 – 18:39 Prioritize early glycaemic control John Wilding (UK) 18:39 – 18:46 Kidney Protection: CREDENCE study under the magnifying glass David Wheeler (UK) 18:46 – 18:53 Do not forget the heart: Diabetes and Cardiovascular […]

Ertugliflozin in the Holistic-Person Centered Approach to T2DM Management

MSD |
Tuesday

18:30 – 18:35 Opening Remarks 18:35 – 18:45 Ertugliflozin & Glycemic Management in the Holistic-Person Centered Approach to T2DM Management Sam Dagogo-Jack (USA) 18:45 – 18:55 Ertugliflozin & Weight Management in the Holistic-Person Centered Approach to T2DM Management 18:55 – 19:05 Ertugliflozin & Cardiovascular Risk Factor and Cardiorenal Protection Management in the Holistic-Person Centered Approach to T2DM […]

Emerging Role of the Hepatic Thyroid Hormone Pathway in the Pathophysiology of NASH 

Madrigal Pharmaceuticals |
Monday

Chair: Michael Roden (GER) 13:30 – 13:35 Introduction Michael Roden (GER) 13:35 – 13:50 NASH: a growing unmet therapeutic need Jörn Schattenberg (GER) 13:50 – 14:05 The underestimated role of thyroid hormone pathway in the pathophysiology of NASH Eveline Bruinstroop (NLD) 14:05 – 14:20 Discussion and Q&As Michael Roden (GER)Jörn Schattenberg (GER)Eveline Bruinstroop (NLD) 14:20 – […]